

Doc code: IDS

Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (01-10)

Approved for use through 07/31/2012. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		12562621
	Filing Date		2009-09-18
	First Named Inventor	GANT, Thomas G.	
	Art Unit	1614	
	Examiner Name		
	Attorney Docket Number	APX0125-201-US	

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	2830993		1958-04-15	BROSSI, A	
	2	3045021		1962-07-17	BROSSI, A	
	3	4316897		1982-02-23	LOTZ, Wolfgang	
	4	7517990	B2	2009-03-14	ITO, et al	
	5	6603008	B1	2003-08-05	ANDO et al.	
	6	6221335	B1	2001-04-24	FOSTER, Robert	
	7	6440710	B1	2002-08-27	KEINAN et al.	
If you wish to add additional U.S. Patent citation information please click the Add button.						Add
U.S.PATENT APPLICATION PUBLICATIONS						Remove

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		12562621	
	Filing Date		2009-09-18	
	First Named Inventor	GANT, Thomas G.		
	Art Unit		1614	
	Examiner Name			
	Attorney Docket Number		APX0125-201-US	

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20020013372	A1	2002-01-13	EKINS, Sean	
	2	20080033011	A1	2008-02-07	TUNG, Roger	
	3	20100113496	A1	2010-05-06	GANT, Thomas G. et al	
	4	20100189698	A1	2010-07-29	WILLIS, Gregory	
	5	20100204258	A1	2010-08-12	HARRIS et al.	
	6	20070197695	A1	2007-08-23	POTYEN et al.	
	7	20120003330	A1	2012-01-05	GANT, Thomas G. et al	

If you wish to add additional U.S. Published Application citation information please click the Add button. **Add**

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	199526325	WO	A2	1995-10-05	Isotechnika, Inc.		<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		12562621	
	Filing Date		2009-09-18	
	First Named Inventor	GANT, Thomas G.		
	Art Unit		1614	
	Examiner Name			
	Attorney Docket Number		APX0125-201-US	

	2	2007130365	WO	A2	2007-11-15	University of Pennsylvania, University of Michigan		<input type="checkbox"/>
	3	2008058261	WO	A1	2008-05-15	Neurocrine Biosciences, Inc		<input type="checkbox"/>
	4	2005077946	WO	A1	2005-08-25	Cambridge Laboratories Limited		<input type="checkbox"/>
	5	2010044981	WO	A2	2010-04-22	Auspex Pharmaceuticals, Inc.		<input type="checkbox"/>
	6	2010044981	WO	A3	2010-06-17	Auspex Pharmaceuticals, Inc.		<input type="checkbox"/>
	7	2011019956	WO	A2	2011-02-17	Biovail Laboratories International		<input type="checkbox"/>
	8	2009124357	WO	A1	2009-10-15	Eutick, Malvin		<input type="checkbox"/>
	9	2010018408	WO	A2	2010-02-18	Biovail Laboratories International		<input type="checkbox"/>
	10	2008112278	WO	A2	2008-09-18	Columbia University in the City of New York		<input type="checkbox"/>
	11	2009003226	WO	A1	2009-01-08	Clarencew PTY LTD		<input type="checkbox"/>
	12	2006053067	WO	A2	2006-05-18	Prestwick Pharmaceuticals, Inc.		<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		12562621	
	Filing Date		2009-09-18	
	First Named Inventor	GANT, Thomas G.		
	Art Unit	1614		
	Examiner Name			
	Attorney Docket Number	APX0125-201-US		

	13	2011106248	WO	A2	2011-09-01	Auspex Pharmaceuticals, Inc.	<input type="checkbox"/>
	14	2011106248	WO	A3	2011-09-01	Auspex Pharmaceuticals, Inc.	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button **Add**

NON-PATENT LITERATURE DOCUMENTS

Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	Bauer, LA et. al.; 0Influence of long-term infusions on lidocaine kinetics, Clin. Pharmacol. Ther. 1982, 433-7	<input type="checkbox"/>
	2	Borgstrom, L et al.; Comparative Pharmacokinetics of Unlabeled and Deuterium-Labeled Terbutaline: Demonstration of a Small Isotope Effect, J Pharm Sci, 1988, 77(11), 952-4	<input type="checkbox"/>
	3	Browne, T.R.; Chapter 2. Isotope Effect: Implications for Pharmaceutical Investigations, Pharm_Lib_1997_13	<input type="checkbox"/>
	4	Browne, T.R. et al.; Pharmacokinetic Equivalence of Stable-Isotope-Labeled and Unlabeled Drugs. Phenobarbital in Man, J Clin Pharmacol, 1982, 22, 309-315	<input type="checkbox"/>
	5	Burm, AGL et al.; Pharmacokinetics of Lidocaine and bupivacaine and stable isotope-labeled analogs: a study in healthy volunteers, Biopharmaceutics and Drug Disposition, 1988, 9, 85-95	<input type="checkbox"/>
	6	Elison, C et al.;Effect of Deuteration of N-CH ₃ Group on Potency and Enzymatic N-Demethylation of Morphine, Science, 1961, 134(3485), 1078-9	<input type="checkbox"/>
	7	Farmer, PB, et al.;Synthesis, Metabolism, and Antitumor Activity of Deuterated Analogues of 1-(2-Choloroethyl)-3-cyclohexyl-1-nitrosourea, Journal of Medicinal Chemistry, 1978, Vol. 21, No. 6, 514-20	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	12562621
	Filing Date	2009-09-18
	First Named Inventor	GANT, Thomas G.
	Art Unit	1614
	Examiner Name	
	Attorney Docket Number	APX0125-201-US

8	Fisher, MB, et al.; The complexities inherent in attempts to decrease drug clearance by blocking sites of CYP-mediated metabolism, <i>Curr Opin Drug Discov Develop</i> ; 2006, 9(1), 101-9	<input type="checkbox"/>
9	Foster, AB; Deuterium Isotope Effects in Studies of Drug Metabolism, <i>Trends in Pharmacological Sciences</i> , Dec 1984, 524-7	<input type="checkbox"/>
10	Helfenbein, J et al.; Isotopic Effect Study of Propofol Deuteration on the Metabolism, Activity, and Toxicity of the Anesthetic, <i>J. Med. Chem.</i> 2002, 45, 5806-5808	<input type="checkbox"/>
11	Kushner, DJ et al.; Pharmacological uses and perspectives of heavy water and deuterated compounds, <i>Can J Phys Pharm</i> 1999, 77, 79-88	<input type="checkbox"/>
12	Lee, H et al.; Deuterium Magic Angle Spinning Studies of Substrates Bound to Cytochrome P450, <i>Biochemistry</i> 1999, 38, 10808-10813	<input type="checkbox"/>
13	Mamada, K et al.; Pharmacokinetic Equivalence of Deuterium-Labeled and Unlabeled Phenytoin, <i>Drug Metabolism and Disposition</i> , 1986, 14(4), 509-11	<input type="checkbox"/>
14	Nelson, SD et al.; The Use of Deuterium Isotope Effect to Probe the Active Site Properties, Mechanism of Cytochrome P450-catalyzed Reactions, and Mechanisms of Metabolically Dependent Toxicity, <i>DRUG METABOLISM AND DISPOSITION</i> 31:1481-1498, 2003	<input type="checkbox"/>
15	Nelson, SD et al.; Primary and B-Secondary Deuterium Isotope Effects in N-Deethylation Reactions, <i>Journal of Medicinal Chemistry</i> , 1975, Vol. 18, No. 11	<input type="checkbox"/>
16	Pohl, LR et al.; Determination of toxic Pathways of Metabolism by Deuterium Substitution, <i>Drug_Metabolism_Rev_1985_1335</i>	<input type="checkbox"/>
17	Rampe, D et al.; Deuterated Analogs of verapamil and nifedipine. Synthesis and biological activity, <i>Eur J Med Chem</i> (1993) 28,259-263	<input type="checkbox"/>
18	Toronto Research Chemicals, Inc.; Tetrabenazine-d7, http://www.trc-canada.com/details.php?CatNumber=T284002	<input type="checkbox"/>

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.